Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 121,039

Document Document Title
WO/2017/016669A1
The present invention relates to substituted amide derivatives of formula (I) having dual pharmacological activity towards both the sigma (σ) receptor, and the p-opioid receptor, to processes of preparation of such compounds, to pharmac...  
WO/2017/017453A1
The present invention provides a transdermal patch comprising: a drug-containing layer comprising (R)-dihydroetorphine, or a salt or a hydrate thereof, and a poly(meth)acrylate; and a backing layer.  
WO/2017/019616A1
Compositions and methods for treating addiction in a subject are disclosed. In particular, compositions and methods for treating addiction to a dopaminergic psychostimulant are disclosed. In some embodiments, addiction is treated by agon...  
WO/2017/015049A1
Methods of treating developmental disorders such as Angelman syndrome, Fragile X syndrome, Fragile X-associated tremor/ataxia syndrome (FXTAS), Autistic Spectrum Disorder, Autism, Asperger's syndrome, pervasive developmental disorder, Ch...  
WO/2017/015349A1
A combination of a muscarinic receptor antagonist consisting of a M2-receptor antagonist and of a non-selective, peripheral anticholinergic agent, and optionally an anticholinesterase inhibitor, and use of the same for treatment of hypoc...  
WO/2017/013599A1
A method of preventing, alleviating or treating traumatic brain injury in an individual comprises administering to the individual a therapeutically effective and physiologically acceptable amount of an agent capable of reducing the amoun...  
WO/2017/012579A1
Disclosed are substituted indole compounds and use methods and uses thereof. The present invention particularly relates to novel indole compounds and pharmaceutical compositions comprising the compounds, for inhibiting re-uptake of 5-hyd...  
WO/2017/014315A1
Provided is an EP2 agonist having a high safety. A compound represented by general formula (I) (wherein each symbol is as defined in the description), a salt thereof, an N-oxide derivative thereof, a solvate of the same or a prodrug of t...  
WO/2017/015491A1
A composition of matter comprising an adeno-associated virus (AAV) or other human compatible virus, encoding the gene for Sialidase Neu3, B3Galt4, St3Gal2, or combinations thereof, and a neuron specific promoter, wherein the composition ...  
WO/2017/012502A1
The present invention relates quinazolinone compounds of Formula (I), as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses; wherein the compounds or pharmaceut...  
WO/2017/013492A1
The present disclosure provides compositions comprising 15-HEPE for use in treating and/or preventing cancer and neurological diseases in a subject in need thereof.  
WO/2017/012088A1
An extraction method for a bird's nest extract comprises: extracting a broken bird's nest aqueous solution for 30 minutes to 12 hours at the temperature of 30 to 60°C, and stirring and vacuumizing the solution at the same time; then adj...  
WO/2017/012576A1
Disclosed are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for examp...  
WO/2017/012599A1
The present invention relates to 5-substituted-7-[4-(substituted)benzyl]amino-3- isopropylpyrazolo[4,3-d]pyrimidines of formula (I) which are effective inhibitors od cyclin- dependent kinases and exhibit strong anti-inflammatory properti...  
WO/2017/014162A1
The purpose of the present invention is to provide: an amyloid β fibril-decomposing agent which contains a naturally occurring substance as an active ingredient; a therapeutic or prophylactic agent for a disease associated with amyloid ...  
WO/2017/011863A1
The invention relates to disulfide-rich peptides derived from spider venom and their use, particularly as neuroprotective agents. The invention also relates to nucleic acid molecules encoding the peptides as well as constructs and host c...  
WO/2017/013496A1
The compound (-)-tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride ((-)-ANAVEX2-73, (-)A2-73, (-)AE 37) has been found to exhibit selectivity for sigma-1 (σ1) receptors and stronger agonist activity at the muscarinic...  
WO/2017/013498A3
Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) are disclosed and characteriz...  
WO/2017/014170A1
Provided are: a heterocyclic compound which has an HDAC-inhibiting activity and is useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancer, central nervous system diseases including...  
WO/2017/013498A2
Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) are disclosed and characteriz...  
WO2017009711A1
Phospholipid preparations for the improvement of sleep and/or treatment of sleep disorders. Methods of improving sleep and/or treating sleep disorders comprising administering the same.  
WO2016069801A8
Some embodiments include bacterial species for use in treatment of one or more autism spectrum disorder (ASD), and/or schizophrenia symptoms in a subject in need thereof. The bacterial species can include Bacteroides (e.g., B. fragilis, ...  
WO2017011294A1
The invention provides methods of reducing the frequency of migraine onset in a migraineur, reducing migraine symptoms experienced by a migraineur, augmenting the effects of pharmaceutical intervention to reduce the frequency of migraine...  
WO2016205270A8
The present invention provides dimethyl fumarate (DMF) particles and methods of preparing the DMF particles. Also provided is DMF coated particles comprising DMF particles coated with an enteric coating. The invention also provides vario...  
WO2017010399A1
Provided are compounds having RORγt inhibitory effects represented by formula (I). Compounds represented by formula (I) (wherein L represents -NR1ACO-, -SO2- or the like, A represents a substituted or unsubstituted aromatic carbocyclic ...  
WO2017009650A1
The present invention relates to novel compounds and method for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C- terminal hydrolase L1 (UCHL1) and ub...  
WO2017010538A1
Provided are a carnosine dipeptidase 1 inhibitor composition, a use for a material that inhibits carnosine dipeptidase 1, and a method for inhibiting carnosine dipeptidase 1. The present invention demonstrates the discovery of a plant- o...  
WO2017009852A1
A method of transplantation is disclosed. The method comprising administering to a subject in need of transplantation of cells in suspension, a therapeutically effective amount of anti-third party cells having a central memory T-lymphocy...  
WO2017008686A1
Provided is an adipose-derived stem cell in which a thromboxane A2 receptor (TP) is deactivated or inhibited and/or the activity of a calpain is deactivated or reduced, and/or the activity of a β-catenin is enhanced. Also provided are a...  
WO2016170124A3
The present invention relates to the use of N-Methyl-D-aspartate (NMDA) antagonists at sub-anesthetic doses for the treatment of motor dysfunction in mental or psychiatric disorders with occurrence of aggressive and/or impulsive behavior.  
WO2016016380A8
The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ("mGluR2"). The invention is also directed to pharma...  
WO2017009750A1
Methods, compositions, and kits for diagnosing or treating neurodegenerative or neuroinflammatory conditions are provided. Also provided are methods for identifying modulators of neurodegenerative or neuroinflammatory conditions.  
WO2017009454A1
The present invention relates to novel compounds that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission ...  
WO2017008737A1
Disclosed is a natural medicinal composition for treating involutional melancholia and atypical depressive disorder and use thereof. The formulation of the composition consists in mass percentage of 70%-97.5% sea buckthorn fruit oil and ...  
WO2017008205A1
Provide the compound of generic formula I: The compound can be useful as A2A-receptor antagonist. Use the compound for the preparation of a medicament for the treatment and/or prevention of diseases associated with inhibiting the recepto...  
WO2017010520A1
A composition for protecting optic nerve cells, for preventing or treating glaucoma, for suppressing retinal ganglionic cell death, or slowing the progression of vision loss in humans containing at least one selected from the group consi...  
WO/2017/009274A1
The present invention relates to compounds of formula (I) wherein R1' is CH3; R1 is methyl, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1' and R1 may form together a 1,1 -dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, methyl, ethy...  
WO2016199170A3
The present invention disclosed relates to Paliperidone palmitate particles, a process to manufacture the same and pharmaceutical compositions thereof. It further relates to the use of such pharmaceutical compositions in the treatment of...  
WO2017011556A1
The disclosure provides novel forms of phosphorylated tau species and applications thereof, as well as methods of diagnosing and/or treating tau-associated neurodegeneration.  
WO/2017/009308A3
The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396), as well as to methods of using these molecules and...  
WO2017009275A1
The present invention relates to compounds of formula I wherein R1 is lower alkyl; R2 is phenyl or pyridinyl, wherein the N atom in the pyridinyl group may be in different positions; n is 0, 1 or 2; V/U are independently from each other ...  
WO/2017/009312A1
The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse L...  
WO2017009472A1
The present invention relates to the use of amitriptyline as an inhibitor of connexin hemichannels (HC) in the Central Nervous System (CNS). This HC-blocking agent is advantageously used to treat disorders involving misregulated HC (nota...  
WO2017010537A1
Provided are a carnosine dipeptidase 1 inhibitor composition, a use for said composition in order to inhibit carnosine dipeptidase 1, and a method for inhibiting carnosine dipeptidase 1. The present invention demonstrates the discovery o...  
WO2017008638A1
Provided is a recombinant P particle formed from a norovirus capsid P protein of a chimeric A beta 1-m peptide (m being an integer between 6 and 15), wherein the recombinant P particles form an ordered and repetitive antigen array. Also ...  
WO/2017/010133A1
Provided are a carnosine dipeptidase 1 inhibitor composition, a use for a material that inhibits carnosine dipeptidase 1, and a method for inhibiting carnosine dipeptidase 1. The present invention demonstrates the discovery of a plant- o...  
WO2017011352A1
Disclosed herein are bone marrow stromal cells. The bone marrow stromal cells may express and/or secrete TGF-βΙ. The bone marrow stromal cells may express CXCR4. Also disclosed herein is a method of treating pain in a subject in need t...  
WO2017010414A1
The invention addresses the problem of providing a cell construct of at least a predetermined size that can be produced in a short period of time, and a method for producing the cell construct. The invention provides a cell construct inc...  
WO2016160574A3
The application relates to novel compounds and their use in treating and preventing diseases and conditions mediated by modulation of voltage-gated sodium channels. Novel aryl- and heteroaryl- pyrrolidine-2-carboxamide compounds and phar...  
WO/2017/007938A1
Substituted 4-azaindoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B rece...  

Matches 251 - 300 out of 121,039